ABBV Overview
Upcoming Projects (ABBV)
-
A Third Opinion: Diving into the recent data from the Phase 3 WAYPOINT clinical trial of TEZSPIRE in patients with chronic rhinosinusitis with nasal polyps
Tickers: AMGN, ABBV
Scheduled For: Nov 22, 2024 at 01:30 PM EST
Executed Projects (ABBV)
-
A Second Opinion: Diving into the recent data from the Phase 3 WAYPOINT clinical trial of TEZSPIRE in patients with chronic rhinosinusitis with nasal polyps
Tickers: AMGN, ABBV
Executed On: Nov 20, 2024 at 12:00 PM EST -
Diving into the recent data from the Phase 3 WAYPOINT clinical trial of TEZSPIRE in patients with chronic rhinosinusitis with nasal polyps
Tickers: AMGN, ABBV
Executed On: Nov 14, 2024 at 11:00 AM EST -
Q4 #3 Discussing the current treatment landscape and the use of Skyrizi (risankizumab-rzaa) for patients with Crohn's disease.
Ticker: ABBV
Executed On: Nov 08, 2024 at 11:00 AM EST -
A Third View: Prescriber check in with gastroenterologists on their impression of Skyrizi in treating Ulcerative colitis
Ticker: ABBV
Executed On: Oct 29, 2024 at 04:30 PM EDT -
A Third Look: Checking in with a prescriber of Rinvoq (upadacitinib) for the treatment of ulcerative colitis.
Ticker: ABBV
Executed On: Oct 25, 2024 at 09:00 AM EDT -
A Second Opinion: An updated look at REGENXBIO Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Tickers: RGNX, ABBV
Executed On: Oct 25, 2024 at 08:00 AM EDT -
An updated look at REGENXBIO Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Tickers: RGNX, ABBV
Executed On: Oct 24, 2024 at 11:15 AM EDT -
Q4 #2 Discussing the current treatment landscape and the use of Skyrizi (risankizumab-rzaa) for patients with Crohn's disease.
Ticker: ABBV
Executed On: Oct 22, 2024 at 04:00 PM EDT -
Q4 #1 Discussing the current treatment landscape and the use of Skyrizi (risankizumab-rzaa) for patients with Crohn's disease.
Ticker: ABBV
Executed On: Oct 10, 2024 at 05:00 PM EDT -
A Third Look: Discussing the potential of AbbVie and Cerevel's Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM) for Schizophrenia
Ticker: ABBV
Executed On: Oct 03, 2024 at 09:00 AM EDT -
Discussing the current treatment landscape and the use of Skyrizi (risankizumab-rzaa) for patients with Crohn's disease.
Ticker: ABBV
Executed On: Sep 24, 2024 at 04:00 PM EDT -
A Second Look: Checking in with a prescriber of Rinvoq (upadacitinib) for the treatment of ulcerative colitis.
Ticker: ABBV
Executed On: Sep 17, 2024 at 11:00 PM EDT -
Checking in with a prescriber of Rinvoq (upadacitinib) for the treatment of ulcerative colitis.
Ticker: ABBV
Executed On: Sep 12, 2024 at 05:00 PM EDT -
A Second Look: Discussing the potential of AbbVie and Cerevel's Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM) for Schizophrenia
Ticker: ABBV
Executed On: Aug 29, 2024 at 04:00 PM EDT -
A Second View: Prescriber check in with gastroenterologists on their impression of Skyrizi in treating Ulcerative colitis
Ticker: ABBV
Executed On: Aug 15, 2024 at 03:00 PM EDT -
Prescriber check in with gastroenterologists on their impression of Skyrizi in treating Ulcerative colitis
Ticker: ABBV
Executed On: Aug 13, 2024 at 01:30 PM EDT -
Discussing the potential of AbbVie and Cerevel's Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM) for Schizophrenia
Ticker: ABBV
Executed On: Aug 06, 2024 at 04:30 PM EDT -
A Second Opinion: Discussing Cerevel Therapeutics Topline Results for Tavapadon in the Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Tickers: CERE, ABBV
Executed On: May 09, 2024 at 12:00 PM EDT -
Discussing Cerevel Therapeutics Topline Results for Tavapadon in the Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Tickers: CERE, ABBV
Executed On: May 01, 2024 at 11:00 AM EDT -
Discussing the potential of epcoritamab (EPKINLY) for the treatment of adult patients with relapse/refractory FL and the top-line results from the Phase 1/2 EPCORE NHL-1 study.
Ticker: ABBV
Executed On: Feb 15, 2024 at 11:00 AM EST -
A Third View: Investigating the Phase 2 AAVIATE clinical trial of ABBV-RGX-314 in patients with Wet AMD.
Tickers: RGNX, ABBV
Executed On: Feb 02, 2024 at 09:30 AM EST -
A Second View: Investigating the Phase 2 AAVIATE clinical trial of ABBV-RGX-314 in patients with Wet AMD.
Tickers: RGNX, ABBV
Executed On: Jan 25, 2024 at 05:00 PM EST -
Investigating the Phase 2 AAVIATE clinical trial of ABBV-RGX-314 in patients with Wet AMD.
Tickers: RGNX, ABBV
Executed On: Jan 23, 2024 at 11:30 AM EST -
A Third Look: Discussing the current treatment landscape and use of oral medications for migraines with a Neurologist.
Tickers: PFE, ABBV
Executed On: Oct 26, 2023 at 05:00 PM EDT -
A Third View: Discussing the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo
Tickers: ABBV, INCY
Executed On: Oct 26, 2023 at 12:00 PM EDT -
A Second Look: Discussing the current treatment landscape and use of oral medications for migraines.
Tickers: PFE, ABBV
Executed On: Oct 25, 2023 at 03:30 PM EDT -
A Second View: Discussing the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo
Tickers: ABBV, INCY
Executed On: Oct 20, 2023 at 01:00 PM EDT -
Discussing the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo
Tickers: ABBV, INCY
Executed On: Oct 19, 2023 at 02:00 PM EDT -
Discussing the current treatment landscape and use of oral medications for migraines.
Tickers: PFE, ABBV
Executed On: Oct 19, 2023 at 12:00 PM EDT -
A Third Opinion: Discussing the Phase 3 SEQUENCE clinical trial of SKYRIZI versus STELARA for the treatment of Crohn's Disease.
Tickers: ABBV, JNJ
Executed On: Sep 27, 2023 at 03:00 PM EDT -
A Second Opinion: Discussing the Phase 3 SEQUENCE clinical trial of SKYRIZI versus STELARA for the treatment of Crohn's Disease.
Tickers: ABBV, JNJ
Executed On: Sep 21, 2023 at 04:45 AM EDT -
Discussing the Phase 3 SEQUENCE clinical trial of SKYRIZI versus STELARA for the treatment of Crohn's Disease.
Tickers: ABBV, JNJ
Executed On: Sep 20, 2023 at 05:00 PM EDT -
Discussing the the potential of EPKINLY (epcoritamab-bysp) for patients with relapsed or refractory diffuse large B-cell lymphoma.
Ticker: ABBV
Executed On: Aug 22, 2023 at 03:30 PM EDT -
A Second Opinion: Discussing data from the Phase 4 Phase 4 IMMpulse study regarding AbbVie's SKYRIZI (risankizumab) for treatment of moderate plaque psoriasis
Ticker: ABBV
Executed On: Aug 17, 2023 at 12:30 PM EDT -
Discussing data from the Phase 4 Phase 4 IMMpulse study regarding AbbVie's SKYRIZI (risankizumab) for treatment of moderate plaque psoriasis
Ticker: ABBV
Executed On: Aug 03, 2023 at 12:00 PM EDT -
A Third View: Understanding the recent label expansion of LILETTA (levonorgestrel-releasing intrauterine system), from Abbvie and Medicines360 as a treatment for heavy menstrual bleeding.
Ticker: ABBV
Executed On: Jul 24, 2023 at 01:30 PM EDT -
A Second View: Understanding the recent label expansion of LILETTA (levonorgestrel-releasing intrauterine system), from Abbvie and Medicines360 as a treatment for heavy menstrual bleeding.
Ticker: ABBV
Executed On: Jul 20, 2023 at 04:45 PM EDT -
Understanding the recent label expansion of LILETTA (levonorgestrel-releasing intrauterine system), from Abbvie and Medicines360 as a treatment for heavy menstrual bleeding.
Ticker: ABBV
Executed On: Jul 18, 2023 at 03:40 PM EDT -
A third look at the potential of IL-23 inhibitors like SKYRIZI (risankizumab) in patients with ulcerative colitis and the top-line results from the Phase 3 COMMAND maintenance study.
Ticker: ABBV
Executed On: Jun 29, 2023 at 01:15 PM EDT -
A second look at the potential of IL-23 inhibitors like SKYRIZI (risankizumab) in patients with ulcerative colitis and the top-line results from the Phase 3 COMMAND maintenance study.
Ticker: ABBV
Executed On: Jun 28, 2023 at 12:30 PM EDT -
A look at the potential of IL-23 inhibitors like SKYRIZI (risankizumab) in patients with ulcerative colitis and the top-line results from the Phase 3 COMMAND maintenance study.
Ticker: ABBV
Executed On: Jun 27, 2023 at 03:00 PM EDT -
A Third Look: Discussing the potential of RINVOQ® (upadacitinib) in moderate to severe Crohn's disease with a gastroenterologist.
Ticker: ABBV
Executed On: Jun 12, 2023 at 04:30 PM EDT -
A Second Look: Discussing the potential of RINVOQ® (upadacitinib) in moderate to severe Crohn's disease with a gastroenterologist.
Ticker: ABBV
Executed On: Jun 08, 2023 at 03:00 PM EDT -
Discussing the potential of RINVOQ® (upadacitinib) in moderate to severe Crohn's disease with a gastroenterologist.
Ticker: ABBV
Executed On: Jun 06, 2023 at 11:00 AM EDT -
Discussing the potential of gene therapies for dry AMD patients, including RegenXbio's RGX-314, for the treatment of dry AMD, DR and additional chronic retinal conditions.
Tickers: RGNX, ABBV
Executed On: May 30, 2023 at 01:00 PM EDT -
A second view: Evaluating the 52-Week Efficacy and Safety study of SKYRIZI (risankizumab) by AbbVie in Plaque Psoriasis Patients released at AAD 2023
Ticker: ABBV
Executed On: May 24, 2023 at 07:00 PM EDT -
A third look: Delving into the data From the SLEek clinical trial on Abbvie's RINVOQ (upadacitinib) in treating patients with Systemic Lupus Erythematosus.
Ticker: ABBV
Executed On: May 22, 2023 at 11:00 AM EDT -
A second look: Delving into the data From the SLEek clinical trial on Abbvie's RINVOQ (upadacitinib) in treating patients with Systemic Lupus Erythematosus.
Ticker: ABBV
Executed On: May 17, 2023 at 04:45 PM EDT -
A third look: Checking in with a prescriber of Abbvie's IMBRUVICA (ibrutinib) for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Ticker: ABBV
Executed On: May 11, 2023 at 09:00 AM EDT -
A second look: Checking in with a prescriber of Abbvie's IMBRUVICA (ibrutinib) for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Ticker: ABBV
Executed On: May 05, 2023 at 11:00 AM EDT -
Checking in with a prescriber of Abbvie's IMBRUVICA (ibrutinib) for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Ticker: ABBV
Executed On: May 05, 2023 at 10:00 AM EDT -
Delving into the data From the SLEek clinical trial on Abbvie's RINVOQ (upadacitinib) in treating patients with Systemic Lupus Erythematosus.
Ticker: ABBV
Executed On: Apr 06, 2023 at 10:00 AM EDT -
Evaluating the 52-Week Efficacy and Safety study of SKYRIZI (risankizumab) by AbbVie in Plaque Psoriasis Patients released at AAD 2023
Ticker: ABBV
Executed On: Mar 24, 2023 at 01:00 PM EDT -
Discussing the current treatment landscape for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and the potential of Zanubrutinib(BRUKINSA®) and the phase 3 ALPINE trial.
Tickers: BGNE, AZN, ABBV
Executed On: Nov 04, 2022 at 09:15 AM EDT -
A second look at the standard of care for chronic graft-versus-host disease and the future use of ibrutinib and ruxolitinib in the pediatric population
Tickers: INCY, ABBV, JNJ, SNY
Executed On: Oct 28, 2022 at 10:30 AM EDT -
A look at the standard of care for chronic graft-versus-host disease and the future use of ibrutinib and ruxolitinib in the pediatric population
Tickers: ABBV, JNJ, SNY, INCY
Executed On: Oct 26, 2022 at 12:00 PM EDT -
A Second look: Evaluating the efficacy and safety of Risankizumab (SKYRIZI) in Crohn's disease
Ticker: ABBV
Executed On: Oct 07, 2022 at 10:30 AM EDT -
Evaluating the efficacy and safety of Risankizumab (SKYRIZI) in Crohn's disease
Ticker: ABBV
Executed On: Aug 26, 2022 at 03:00 PM EDT -
A Third Look at the approved Abbvie's Humira and the general landscape of HS treatments on the horizon
Tickers: ABBV, NVS, ANAB
Executed On: Aug 05, 2022 at 01:00 PM EDT -
A Second Look at the approved Abbvie's Humira and the general landscape of HS treatments on the horizon
Tickers: ABBV, NVS, ANAB
Executed On: Aug 05, 2022 at 08:30 AM EDT -
A Look at the use of Abbvie's Humira as an approved treatment for Hidradenitis Suppurativa and the landscape of potential new treatments on the horizon
Tickers: ABBV, NVS
Executed On: Aug 04, 2022 at 01:00 PM EDT -
Checking on the launch of Ingrezza for treating patients with Tardive Dyskinesia
Tickers: NBIX, ABBV
Executed On: May 23, 2022 at 01:00 PM EDT -
A Fourth Take: Discussing the potential of VUITY in treating presbyopia
Ticker: ABBV
Executed On: Mar 29, 2022 at 05:30 PM EDT -
A Third Opinion: Discussing the potential of VUITY in treating presbyopia
Ticker: ABBV
Executed On: Mar 28, 2022 at 10:00 AM EDT -
A Second Look: Discussing the potential of VUITY in treating presbyopia
Ticker: ABBV
Executed On: Mar 25, 2022 at 11:30 AM EDT -
Discussing the potential of VUITY in treating presbyopia
Ticker: ABBV
Executed On: Mar 24, 2022 at 04:30 PM EDT -
Overview of Migraine therapies - Biohaven - 2nd look
Tickers: BHVN, ABBV
Executed On: Jan 07, 2022 at 11:00 AM EST -
Overview of Migraine therapies - Biohaven
Tickers: BHVN, ABBV
Executed On: Jan 03, 2022 at 02:00 PM EST
Upcoming & Overdue Catalysts (ABBV)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ABBV)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
